Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Ductal × exemestane × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 93 Neoplasm Metastasis 6 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Endometrial Neoplasms 2 Breast Diseases 2 Breast Cancer Metastatic 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Primary Breast Cancer ER+ve 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1 Multiple Endocrine Neoplasia Type 1 1 Metastatic Beast Cancer 1 Mammary Neoplasms, Animal 1 Locoregional Recurrence 1 Lethal Congenital Contracture Syndrome 2 1 Hyperglycemia 1 Hormone Receptor Positive Malignant Neoplasm of Breast 1 HER2-positive Breast Cancer 1 Granulosa cell tumor of the ovary 1 Estrogen-receptor Positive Invasive Metastatic Breast Cancer 1 Endometrial Stromal Tumors 1 Endometrial Hyperplasia 1 ER+ Breast Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Carcinoma, Ductal 1 Bulbo-Spinal Atrophy, X-Linked 1

Interventions

exemestane 1 Tamoxifen 1 Pemetrexed 1 Doxorubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07499999 2026-03-30

BabyTEARS

Dana-Farber Cancer Institute

Phase 2 Not yet recruiting

Breast Neoplasms, Carcinoma, Ductal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡